The high expression of PD-L1 and CTLA4 in the low-risk group not only demonstrated that the IGBRS is an efficient classifier of risk stratification in CRC and closely related to tumor immunity but also suggested that the IGBRS may be a reference for the classification of CRC patients treated with immune checkpoint inhibitors. This evidence concerns the gene CTLA4 and colorectal carcinoma.